Taysha Gene Therapies (TSHA) Share-based Compensation (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Share-based Compensation of $28.1 million for Q1 2026, up 696.26% sequentially from $3.5 million in Q4 2025, and up 753.07% YoY from $3.3 million in Q1 2025.
Taysha Gene Therapies (TSHA) Share-based Compensation (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Share-based Compensation for 7 years, with the latest figure at $28.1 million in Q1 2026.
- Quarterly Share-based Compensation rose 753.07% year-over-year to $28.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.1 million (up 112.89% YoY) and the FY2025 annual result came in at $13.3 million, down 14.21% from the prior year.
- Share-based Compensation rose to $28.1 million in Q1 2026 per TSHA's latest filing, from $3.5 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $28.1 million in Q1 2026 and troughed at $1.7 million in Q1 2023.
- A 5-year average of $4.7 million and a median of $3.3 million in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation plunged 68.57% in 2023, then soared 753.07% in 2026.
- Over 5 years, Share-based Compensation stood at $4.1 million in 2022, then sank by 52.04% to $2.0 million in 2023, then surged by 63.41% to $3.2 million in 2024, then gained by 9.73% to $3.5 million in 2025, then soared by 696.26% to $28.1 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $28.1 million, $3.5 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 5.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.81 Mn |
| Jun 30, 2026 | 5.81 Mn |
| Mar 31, 2026 | 28.10 Mn |
| Mar 31, 2026 | 28.10 Mn |
| Dec 31, 2025 | 3.53 Mn |
| Dec 31, 2025 | 3.53 Mn |
| Sep 30, 2025 | 3.29 Mn |
| Sep 30, 2025 | 3.29 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Mar 31, 2025 | 3.29 Mn |
| Mar 31, 2025 | 3.29 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Mar 31, 2024 | 3.20 Mn |
| Mar 31, 2024 | 3.20 Mn |